Insider Transactions in Q2 2024 at Revance Therapeutics, Inc. (RVNC)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2024
|
Tobin Schilke CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.51%
|
$2,000
$2.18 P/Share
|
|
Jun 30
2024
|
Mark J Foley CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.1%
|
$2,000
$2.18 P/Share
|
|
May 01
2024
|
Julian S Gangolli Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+24.96%
|
-
|
|
May 01
2024
|
Carey O Connor Kolaja Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+32.22%
|
-
|
|
May 01
2024
|
Chris Nolet Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+25.59%
|
-
|
|
May 01
2024
|
Angus C. Russell Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+22.55%
|
-
|
|
May 01
2024
|
Olivia C Ware Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+32.14%
|
-
|
|
May 01
2024
|
Jill Beraud Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+25.59%
|
-
|
|
May 01
2024
|
Vlad Coric Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+41.92%
|
-
|
|
Apr 16
2024
|
Erica Jordan Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,392
-2.04%
|
$7,176
$3.8 P/Share
|